Tests a radioactive tracer scan in people with liver cancer
Compares a Ga68-FAPI-46 PET/MRI scan with standard MRI in liver cancer patients.
Plain-language title generated from the registry record
Registry title: Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma
Key facts
- Where
- Singapore, SingaporeSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 99 years old?
Source: NCT05687747, who can take part
Where in Singapore
- Robert John WalshSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National University Hospital, Singapore
- Trial code
- NCT05687747
- Record updated
- 4 April 2025
- Original description
Single centre prospective evaluation of 68Gallium(Ga68)-FAPI-46 PET/MRI in patients diagnosed with Hepatocellular Carcinoma (HCC). 68Gallium-FAPI-46 PET/MRI and standard contrasted multiphasic MRI imaging will be acquired in patients with radiological or histological diagnosis of HCC. The PET scan results will be compared to standard imaging to evaluate its role in lesion detection, characterisation and staging in patients with HCC.Read full original descriptionShow less
Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma
Single centre prospective evaluation of 68Gallium(Ga68)-FAPI-46 PET/MRI in patients diagnosed with Hepatocellular Carcinoma (HCC). 68Gallium-FAPI-46 PET/MRI and standard contrasted multiphasic MRI imaging will be acquired in patients with radiological or histological diagnosis of HCC. The PET scan results will be compared to standard imaging to evaluate its role in lesion detection, characterisation and staging in patients with HCC.
Inclusion: Age 21-99 years; Diagnosis of HCC based on histological assessment, or meeting consensus radiological criteria for diagnosis of HCC based on American Association for the Study of Liver Diseases practice guidelines(18); No prior locoregional therapy for HCC; Creatinine clearance > 30ml/min based on Cockcroft Gault formula; Able to provide informed signed consent.
Exclusion: Hepatic surgery within the last 30 days; Allergy to 68Ga-FAPI contrast agents; Contraindication to MRI, including but not limited to MRI incompatible metallic implants, cardiac pacemaker, claustrophobia; Known active malignancy other than HCC; Active inflammatory conditions that may affect FAPI imaging in opinion of investigator. Including but not limited to active infection, IgG4-related disease, inflammatory bowel disease,; Pregnancy (all women of childbearing age are required to undertake a urine pregnancy test); Weight > 150kg.